AmpTec

AmpTec GmbH was founded in June 2005. The ExpressArt® technology was developed at artus GmbH. After the acquisition of the PCR branch of artus GmbH by Qiagen AG, the ExpressArt® branch with all its personnel and know-how was transferred to AmpTec GmbH.With ExpressArt® we have overcome several limitations of competing technologies: no large primer-derived amplification artefacts, no problems with studies comprising small and large RNA samples, amplification of picogram amounts of total RNA.

Further Information: http://www.amp-tec.com